Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00270894 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients
A Phase 2 study, sponsored by Accelerated Community Oncology Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00270894 is a Phase 2 study that has completed, run by Accelerated Community Oncology Research Network. The registered enrollment target is 30 participants.
The verdict
NCT00270894, a Phase 2 study, has completed, sponsored by Accelerated Community Oncology Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness and tolerability of the combination of the following medications given every two weeks in HER2 positive breast cancer patients: * trastuzumab (Herceptin) * epirubicin (Ellence) * cyclophosphamide (Cytoxan) * docetaxel (Taxotere)
Interventions
- DRUG cyclophosphamide
- DRUG docetaxel
- DRUG trastuzumab
- DRUG epirubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-11 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00270894
The ClinicalTrials.gov registry entry for NCT00270894 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Accelerated Community Oncology Research Network, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cyclophosphamide is the first listed.
NCT00270894 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00270894 about?
NCT00270894 is a clinical study titled "Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients". The purpose of this study is to evaluate the effectiveness and tolerability of the combination of the following medications given every two weeks in HER2 positive breast cancer patients: * trastuzumab (Herceptin) * epirubicin (Ellence) * cyclophosphamide (Cytoxan) * docetaxel (Taxotere)
What is the current status of trial NCT00270894?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-11. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00270894?
The interventions under investigation include: cyclophosphamide (DRUG), docetaxel (DRUG), trastuzumab (DRUG), epirubicin (DRUG).
Who is sponsoring clinical trial NCT00270894?
This trial is sponsored by Accelerated Community Oncology Research Network, which has 16 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.